The price of Vera Therapeutics Inc (NASDAQ: VERA) closed at $42.57 in the last session, down -8.51% from day before closing price of $46.53. On the day, 1136268 shares were traded.
Ratios:
We take a closer look at VERA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.42 and its Current Ratio is at 7.42. In the meantime, Its Debt-to-Equity ratio is 0.53 whereas as Long-Term Debt/Eq ratio is at 0.50.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on January 25, 2024, initiated with a Outperform rating and assigned the stock a target price of $26.
On December 18, 2023, Raymond James started tracking the stock assigning a Outperform rating and target price of $29.Raymond James initiated its Outperform rating on December 18, 2023, with a $29 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 10 ’24 when Young Joseph R sold 5,714 shares for $40.00 per share. The transaction valued at 228,560 led to the insider holds 53,171 shares of the business.
Grant Sean sold 99,828 shares of VERA for $3,954,516 on Apr 03 ’24. The CHIEF FINANCIAL OFFICER now owns 66,337 shares after completing the transaction at $39.61 per share. On Apr 03 ’24, another insider, Grant Sean, who serves as the CHIEF FINANCIAL OFFICER of the company, sold 18,649 shares for $39.42 each. As a result, the insider received 735,205 and left with 0 shares of the company.
Stock Price History:
Over the past 52 weeks, VERA has reached a high of $50.78, while it has fallen to a 52-week low of $6.07.
Shares Statistics:
A total of 44.45M shares are outstanding, with a floating share count of 39.26M. Insiders hold about 26.90% of the company’s shares, while institutions hold 61.47% stake in the company.
Earnings Estimates
The company has VERS analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $1.25, with high estimates of $4.38 and low estimates of $0.18.
Analysts are recommending an EPS of between $Technology and $Technology for the fiscal current year, implying an average EPS of $Healthcare.
